Ban pharmaceutical contributions to CDC via CDC Foundation
Mandate treats CDC Foundation pharma donations as a conflict of interest that should be banned; broader Goal #5 calls for NIH/CDC/FDA regulators free of private biopharma funding and long cooling-off periods.
Mandate
Mandate Ch. 14 (HHS) — CDC Conflicts of Interest: practice of accepting pharma contributions through CDC Foundation should be banned; Goal #5: NIH/CDC/FDA regulators should be entirely free from private biopharma funding; shut revolving door with lengthy cooling-off (suggests 15 years); decommission CDC and NIH Foundations influenced by pharma boards.
Undo plan
1) Rescind absolute bans that block all philanthropic public-health funding through CDC/NIH foundations without substitute congressional appropriations.
2) Restore transparent foundation governance with conflict firewalls, public donor disclosures, and ethics review rather than opaque corporatism.
3) Enact/maintain cooling-off rules for regulators that are enforceable and proportionate (years, not decades that collapse recruitment).
4) Require congressional oversight reports on industry funding and royalty income of agency leadership.
5) Verify: annual public donor and royalty disclosures; OIG conflict audits.